TACE plus immune checkpoint inhibitor-based systemic therapies for hepatocellular carcinoma

被引：0
作者：
Reiter, Florian P. [1 ]
Geier, Andreas [1 ]
机构：
[1] Univ Hosp Wurzburg, Dept Med 2, Div Hepatol, D-97080 Wurzburg, Germany
来源：
LANCET | 2025年 / 405卷 / 10474期
关键词：
LOCOREGIONAL THERAPIES; END-POINTS; SURVIVAL;
D O I：
10.1016/S0140-6736(24)02680-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：174 / 176
页数：3
相关论文
共 12 条
  • [1] Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol
    Ben Khaled, Najib
    Seidensticker, Max
    Ricke, Jens
    Mayerle, Julia
    Oehrle, Bettina
    Roessler, Daniel
    Teupser, Daniel
    Ehmer, Ursula
    Bitzer, Michael
    Waldschmidt, Dirk
    Fuchs, Martin
    Reuken, Philipp A.
    Lange, Christian M.
    Wege, Henning
    Kandulski, Arne
    Dechene, Alexander
    Venerito, Marino
    Berres, Marie-Luise
    Luedde, Tom
    Kubisch, Ilja
    Reiter, Florian P.
    De Toni, Enrico N.
    [J]. FUTURE ONCOLOGY, 2022, 18 (12) : 1423 - 1435
  • [2] Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival
    Broglio, Kristine R.
    Berry, Donald A.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (23): : 1642 - 1649
  • [3] Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies
    D'Amico, G
    Garcia-Tsao, G
    Pagliaro, L
    [J]. JOURNAL OF HEPATOLOGY, 2006, 44 (01) : 217 - 231
  • [4] Delgado A, 2021, AM J CANCER RES, V11, P1121
  • [5] Evaluation of Tumor Response After Locoregional Therapies in Hepatocellular Carcinoma Are Response Evaluation Criteria in Solid Tumors Reliable?
    Forner, Alejandro
    Ayuso, Carmen
    Varela, Maria
    Rimola, Jordi
    Hessheimer, Amelia J.
    Rodriguez de Lope, Carlos
    Reig, Maria
    Bianchi, Luis
    Llovet, Josep M.
    Bruix, Jordi
    [J]. CANCER, 2009, 115 (03) : 616 - 623
  • [6] Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
    Kudo, Masatoshi
    Finn, Richard S.
    Qin, Shukui
    Han, Kwang-Hyub
    Ikeda, Kenji
    Piscaglia, Fabio
    Baron, Ari
    Park, Joong-Won
    Han, Guohong
    Jassem, Jacek
    Blanc, Jean Frederic
    Vogel, Arndt
    Komov, Dmitry
    Evans, T. R. Jeffry
    Lopez, Carlos
    Dutcus, Corina
    Guo, Matthew
    Saito, Kenichi
    Kraljevic, Silvija
    Tamai, Toshiyuki
    Ren, Min
    Cheng, Ann-Lii
    [J]. LANCET, 2018, 391 (10126) : 1163 - 1173
  • [7] EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization.
    Lencioni, Riccardo
    Kudo, Masatoshi
    Erinjeri, Joseph
    Qin, Shukui
    Ren, Zhenggang
    Chan, Stephen
    Arai, Yasuaki
    Heo, Jeong
    Mai, Ahn
    Escobar, Jose
    Lopez Chuken, Yamil Alonso
    Yoon, Jung-Hwan
    Tak, Won Young
    Suttichaimongkol, Tanita
    Bouattour, Mohamed
    Lin, Shi-Ming
    Zotkiewicz, Magdalena
    Udoye, Stephanie
    Cohen, Gordon
    Sangro, Bruno
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : LBA432 - LBA432
  • [8] Design and endpoints of clinical trials in hepatocellular carcinoma
    Llovet, Josep M.
    Di Bisceglie, Adrian M.
    Bruix, Jordi
    Kramer, Barnett S.
    Lencioni, Riccardo
    Zhu, Andrew X.
    Sherman, Morris
    Schwartz, Myron
    Lotze, Michael
    Talwalkar, Jayant
    Gores, Gregory J.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (10): : 698 - 711
  • [9] Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival
    Llovet, Josep M.
    Montal, Robert
    Villanueva, Augusto
    [J]. JOURNAL OF HEPATOLOGY, 2019, 70 (06) : 1262 - 1277
  • [10] Role of locoregional therapies in the wake of systemic therapy
    Palmer, Daniel H.
    Malagari, Katerina
    Kulik, Laura M.
    [J]. JOURNAL OF HEPATOLOGY, 2020, 72 (02) : 277 - 287
12